BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow G. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol 2017;52:414-9. [PMID: 27887202 DOI: 10.1080/00365521.2016.1259653] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Olbjørn C, Småstuen MC, Moen AEF. Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease. Microorganisms 2022;10:1273. [DOI: 10.3390/microorganisms10071273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Rodrigues M, Bueno C, Lomazi EA, Fernandes MIM, Neufeld CB, D'Amico MFM, Patiño FRA. CLASSICAL SEROLOGICAL MARKERS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE IN BRAZIL. Arq Gastroenterol 2021;58:495-503. [PMID: 34909856 DOI: 10.1590/S0004-2803.202100000-89] [Reference Citation Analysis]
3 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gau CC, Tseng MH, Wu CY, Yang HY, Huang JL. The Impact of Serum Anti-neutrophil Cytoplasmic Antibody on Clinical Characteristics and Outcomes in Pediatric-Onset Systemic Lupus Erythematosus Patients. Front Med (Lausanne) 2021;8:647510. [PMID: 33937288 DOI: 10.3389/fmed.2021.647510] [Reference Citation Analysis]
5 Ricciuto A, Aardoom M, Orlanski-Meyer E, Navon D, Carman N, Aloi M, Bronsky J, Däbritz J, Dubinsky M, Hussey S, Lewindon P, Martín De Carpi J, Navas-López VM, Orsi M, Ruemmele FM, Russell RK, Veres G, Walters TD, Wilson DC, Kaiser T, de Ridder L, Turner D, Griffiths AM; Pediatric Inflammatory Bowel Disease–Ahead Steering Committee. Predicting Outcomes in Pediatric Crohn's Disease for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program. Gastroenterology 2021;160:403-436.e26. [PMID: 32979356 DOI: 10.1053/j.gastro.2020.07.065] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
6 Kuznetsova DА, Lapin SV, Shchukina OB. The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review). Alʹm klin med 2020;48:364-374. [DOI: 10.18786/2072-0505-2020-48-061] [Reference Citation Analysis]
7 Biscaglia G, Piazzolla M, Cocomazzi F, Melchionda G, De Cata A, Bossa F, Palmieri O, Andriulli A. Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. European Journal of Gastroenterology & Hepatology 2020;32:1579-82. [DOI: 10.1097/meg.0000000000001919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 28.0] [Reference Citation Analysis]
9 Kristensen VA, Cvancarova M, Høivik ML, Moum B, Vatn MH. Serological antibodies and surgery in a population-based inception cohort of Crohn’s disease patients – the IBSEN study. Scandinavian Journal of Gastroenterology 2020;55:436-41. [DOI: 10.1080/00365521.2020.1745879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Guo S, Lu Y, Xu B, Wang W, Xu J, Zhang G. A Simple Fecal Bacterial Marker Panel for the Diagnosis of Crohn's Disease. Front Microbiol. 2019;10:1306. [PMID: 31244813 DOI: 10.3389/fmicb.2019.01306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Duarte-Silva M, Afonso PC, de Souza PR, Peghini BC, Rodrigues-Júnior V, de Barros Cardoso CR. Reappraisal of antibodies against Saccharomyces cerevisiae (ASCA) as persistent biomarkers in quiescent Crohn's disease. Autoimmunity 2019;52:37-47. [PMID: 30884988 DOI: 10.1080/08916934.2019.1588889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
12 Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Jahnsen J, Ricanek P, Vatn S, Moen AEF, Tannæs TM, Lindstrøm JC, Söderholm JD, Halfvarson J, Gomollón F, Casén C, Karlsson MK, Kalla R, Adams AT, Satsangi J, Perminow G. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome. Clin Exp Gastroenterol 2019;12:37-49. [PMID: 30774408 DOI: 10.2147/CEG.S186235] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
13 Horn MP, Peter AM, Righini Grunder F, Leichtle AB, Spalinger J, Schibli S, Sokollik C. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease. PLoS One 2018;13:e0208974. [PMID: 30557305 DOI: 10.1371/journal.pone.0208974] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
14 Jiang KF, Fan YH. Serological markers and inflammatory bowel disease: Prevalence of serum markers and their diagnostic value in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2018; 26(25): 1487-1493 [DOI: 10.11569/wcjd.v26.i25.1487] [Reference Citation Analysis]
15 Derkacz A, Olczyk P, Komosinska-Vassev K. Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases. Dis Markers. 2018;2018:7451946. [PMID: 29991970 DOI: 10.1155/2018/7451946] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
16 Velikova TV, Spassova ZA, Milatchkov LM, Panova DG, Ivanova - Todorova EI, Tumangelova - Yuzeir KD, Kurteva EK, Kyurkchiev DS, Deredjan SA, Nikolov RK, Altankova IP, Vladimirova LM. Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease. Ann Colorectal Res 2018;6. [DOI: 10.5812/acr.68674] [Reference Citation Analysis]
17 Smids C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, Wahab PJ, van Lochem EG. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52:1104-1112. [PMID: 28661185 DOI: 10.1080/00365521.2017.1344875] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]